HVIVO PLC — Director's Dealing 2013

Oct 3, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6694P

Venn Life Sciences Holdings PLC

03 October 2013

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Director's Dealing

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that Tony Richardson, a director, has transferred 110,000 ordinary shares from his own name into his pension fund. The shares were transferred at a price of 27p.

There has been no change in Tony Richardson's beneficial shareholding in Venn as a result of this transaction.

Enquiries:

Venn Life Sciences Holdings Plc
Tony Richardson, Chief Executive Officer	Tel: +353 154 99 341
Paul Foulger, Finance Director	Tel: 020 7933 8797
Orla McGuinness, Marketing Manager	Tel: +33 (0)1 30 82 67 07
Zeus Capital (Nominated Adviser and Broker)
Ross Andrews/Andrew Jones(Corporate Finance)	Tel: 0161 831 1512
John Goold (Institutional Sales)	Tel: 020 7016 8925
Walbrook PR Ltd	Tel: 020 7933 8787 or [email protected]
Paul McManus	Mob: 07980 541 893
Lianne Cawthorne	Mob: 07584 391 303

Additional Information:

About Venn Life Sciences Limited: www.vennlifesciences.com

Venn Life Sciences is a Clinical Research Organisation ("CRO") providing a suite of clinical trial management services to pharmaceutical, biotechnology and medical device organisations. With operations in France, Ireland, the Netherlands, Russia, the UK, and a branch office in Switzerland, the Venn Group also includes a Clinical Resourcing business placing experienced clinical teams and individuals on projects throughout Europe. The Company's near term objective is the expansion of its coverage to other European countries through strategic acquisitions and organic growth, offering clients a full service, multi-centred capability in Phase II-IV trials and across a range of principal disease areas.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBBBDGSUGBGXX